Test immunotherapy plus hormone therapy and an AKT blocker
Treatments studied
Part of Cancer, Skin clinical trials.
This trial tests whether combining immunotherapy, hormone therapy, and an AKT-blocking drug can control ER-positive advanced breast cancer in women whose cancer is resistant to hormone treatment. It may help shrink tumors and slow disease by targeting several pathways at once.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have confirmed ER-positive invasive breast cancer (ER level more than 1%).
- Your cancer is advanced or has spread (locally advanced or metastatic) and you have at least one measurable spot on scans.
- You have not had chemotherapy for advanced/metastatic breast cancer.
- Your cancer must be resistant to hormone therapy (it came back within 2 years of adjuvant hormone treatment, or hormone treatments have not worked after up to 2 lines for advanced disease).
- You must be premenopausal or perimenopausal based on menstrual history or hormone blood tests (or you’re on a monthly/ongoing ovarian-suppression shot and can document you were premenopausal before it).
- Your health tests must be within required limits (blood counts, liver/kidney function, and urine protein), and you must be able to give consent and follow study visits.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding a hormone-blocking drug (GnRH agonist) to standard chemotherapy before surgery helps premenopausal women with triple-negative breast cancer. It aims to improve treatment outcomes by targeting hormones that may fuel tumor growth.
This trial tests a new oral drug called capivasertib combined with standard hormone therapy for people with advanced breast cancer that is HR-positive and HER2-negative. It is for those whose cancer has progressed on previous hormone therapy and who have a specific gene change (PIK3CA, AKT1, or PTEN).
This study tests how well and how safely different combinations of cancer drugs work for people with metastatic or inoperable locally advanced breast cancer. It may help by finding a better treatment option and collecting information to guide future care.
This Phase 1b/2 trial tests a combination of pegylated liposomal doxorubicin and pembrolizumab for breast cancer that no longer responds to hormone treatment. It aims to see how well the combination works and how safely it can be given to patients with advanced disease.
This Phase 2 study tests a combination of immune-based treatments along with hormone (endocrine) therapy to slow or shrink advanced, hormone-receptor positive, HER2-negative breast cancer. You may be a candidate if your cancer has progressed after standard hormone-blocking medicines and you can start treatment with CDK4/6 medicine plus an aromatase inhibitor.
This Phase 2 study tests an individualized vaccine made from your tumor information to help your immune system fight hormone-positive breast cancer. You may be able to participate if you meet specific hormone-receptor, health, and treatment-timing requirements.
Hear when a new Premenopausal Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.